Septerna, IPO
Septerna Shares Set for Trading Debut After Upsized IPO
Shares of Septerna are set to maker their trading debut Friday after the clinical-stage biotechnology's upsized initial public offering. The South San Francisco company late Thursday said it is selling 16 million shares at $18 apiece in the IPO, up from prior plans to offer about 15.3 million shares.
Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...
Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...
Septerna is the 23rd biotech to go public this year, raising funds to advance its lead candidate, a treatment for ...
Septerna stock has risen 29%, to $23.31, since it debuted on the exchange Friday. The San Francisco biotechnology company said Thursday it would sell 16 million shares at $18 apiece, giving the ...
Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor ...
Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on ...
Goldman Sachs-backed Septerna would be valued around $750 million. Drug developers have achieved resounding success in the ...
Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback